Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial

医学 耐受性 不利影响 随机对照试验 眼科 可视模拟标度 内科学 外科
作者
Esen K. Akpek,David Wirta,Johnathon Downing,Joseph Tauber,John D. Sheppard,Joseph B. Ciolino,Alice S. Meides,Sonja Krösser
出处
期刊:JAMA Ophthalmology [American Medical Association]
卷期号:141 (5): 459-459 被引量:92
标识
DOI:10.1001/jamaophthalmol.2023.0709
摘要

Importance: Dry eye disease (DED) is a common public health problem with significant impact on vision-related quality of life and well-being of patients. Medications with rapid onset of action and a good tolerability profile remain an unmet need. Objective: To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared with vehicle. Design, Setting, and Participants: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (ESSENCE-2) was a phase 3, multicenter, randomized, double-masked, vehicle-controlled clinical study conducted from December 5, 2020, to October 8, 2021. Following a 14-day run-in period with an artificial tear administered 2 times per day, eligible participants were randomly assigned 1:1 to the treatment groups. Patients with moderate to severe DED were included in the study. Interventions: Cyclosporine solution vs vehicle administered 2 times per day for 29 days. Main Outcomes and Measures: The primary end points were changes from baseline in total corneal fluorescein staining (tCFS; 0-15 National Eye Institute scale) and in dryness score (0-100 visual analog scale) at day 29. Conjunctival staining, central corneal fluorescein staining, and tCFS responders were also assessed. Results: A total of 834 study participants were randomly assigned to cyclosporine (423 [50.7%]) or vehicle (411 [49.3%]) groups at 27 sites. Participants had a mean (SD) age of 57.1 (15.8) years, and 609 (73.0%) were female individuals. The majority of participants self-identified in the following race categories: 79 Asian (9.5 %), 108 Black (12.9%), and 635 White (76.1%). Participants treated with cyclosporine solution had greater improvement in tCFS (-4.0 grades) than the vehicle group (-3.6 grades) at day 29 (change [∆] = -0.4; 95% CI, -0.8 to 0; P = .03). The dryness score showed treatment benefits from baseline in both groups: -12.2 points for cyclosporine and -13.6 points for vehicle (∆ = 1.4; 95% CI, -1.8 to 4.6; P = .38). In the cyclosporine group, 293 participants (71.6%) achieved clinically meaningful reductions of 3 grades or higher in tCFS vs 236 (59.7%) in the vehicle group (∆ = 12.6%; 95% CI, 6.0%-19.3%; P < .001). These responders showed greater improvement in symptoms at day 29 including dryness (∆ = -4.6; 95% CI, -8.0 to -1.2; P = .007) and blurred vision (Δ = -3.5; 95% CI, -6.6 to -4.0; P = .03) compared with nonresponders. Conclusions and Relevance: The ESSENCE-2 trial confirmed that treatment with a water-free cyclosporine solution, 0.1%, results in early therapeutic effects on the ocular surface compared with vehicle. The responder analyses suggest that the effect is clinically meaningful in 71.6% of participants in the cyclosporine group. Trial Registration: ClinicalTrials.gov Identifier: NCT04523129.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haipronl发布了新的文献求助10
刚刚
王某某发布了新的文献求助10
刚刚
asdfghjkl完成签到,获得积分10
刚刚
1秒前
2秒前
核桃发布了新的文献求助10
2秒前
2秒前
2秒前
Hello的应助被阿白采纳,获得10
3秒前
小二郎的应助被阿白采纳,获得10
3秒前
大个的应助被阿白采纳,获得10
3秒前
DW的应助被阿白采纳,获得10
3秒前
或者完成签到 ,获得积分10
3秒前
汉堡包的应助被明天过后采纳,获得10
3秒前
斯文败类的应助被害羞慕晴采纳,获得10
4秒前
可靠的墨镜完成签到 ,获得积分10
4秒前
三井完成签到,获得积分10
4秒前
烟火彼岸完成签到,获得积分10
5秒前
5秒前
古叶完成签到,获得积分10
5秒前
Gogo完成签到 ,获得积分10
5秒前
5秒前
卷卷完成签到 ,获得积分10
6秒前
科研小白完成签到 ,获得积分10
6秒前
Nole的应助被777采纳,获得30
6秒前
walden发布了新的文献求助30
6秒前
7秒前
7秒前
7秒前
7秒前
天天快乐的应助被wsqg123采纳,获得10
7秒前
平和的狍子完成签到 ,获得积分10
8秒前
8秒前
8秒前
YYL发布了新的文献求助10
8秒前
KayneJia给KayneJia的求助进行了留言
8秒前
9秒前
ee完成签到 ,获得积分10
9秒前
彭于晏的应助被李铮采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482